Previous 10 | Next 10 |
Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q3 earnings results on Monday, November 2nd, before market open.The consensus EPS Estimate is $0.97 (+51.6% Y/Y) and the consensus Revenue Estimate is $531.11M (+58.3% Y/Y).Over the last 2 years, HZNP has beaten EPS estimates 100% of...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2020 , ranking number two out of other midsize companies in the Chicago area. “Receiving the Top Workplaces award is especially meaningful...
-- Oral presentation will highlight results from the OPTIC 48-week off-treatment follow-up period, including long-term proptosis (eye bulging) response and diplopia (double vision) improvement -- -- Poster presentation assesses improvement in fellow eye of patients with TED, i...
AGC Biologics and Horizon Therapeutics plc Expand Partnership Horizon's TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics' new facility in Boulder, CO PR Newswire SEATTLE, Oct. 29, 2020 SEATTLE , Oct. 29, 2020 /PRNewswire/ --...
-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in the Infus...
Horizon Therapeutics stock has had a great year to date - the share price has grown from $36, to $77 at the time of writing. Much of this is related to the January approval of Tepezza indicated for thyroid eye disease. Management see the drug as a $3bn revenue driver. The company'...
-- Initial findings from PROTECT study presented during American Society of Nephrology (ASN) Kidney Week 2020 -- -- Horizon to host an online discussion with the primary investigator for PROTECT on Oct. 27 at 7 p.m. ET -- Horizon Therapeutics plc (Nasdaq: HZNP) today...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA ® (teprotumumab-trbw) has been selected as a winner of the 19 th Annual Chicago Innovation Award. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the trea...
Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE’s Best Medium Workplaces 2020 list for the fifth consecutive year. Horizon ranked 10th out of 100 other medium-sized companies. “This recognition from FORTUNE and Great Pla...
-- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year following TEPEZZA treatment for TED, and are supported by recently announced long-te...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...